A number of sentences in the first paragraph of the introduction of \[[@B28-ijms-16-05072]\] were copied verbatim from \[[@B21-ijms-16-05072],[@B22-ijms-16-05072],[@B25-ijms-16-05072],[@B29-ijms-16-05072]\]. Although \[[@B21-ijms-16-05072],[@B22-ijms-16-05072],[@B25-ijms-16-05072]\] were cited in the text, \[[@B29-ijms-16-05072]\] was omitted and it was not made sufficiently clear that direct quotations were used. The authors wish to apologize to the authors of \[[@B21-ijms-16-05072],[@B22-ijms-16-05072],[@B25-ijms-16-05072],[@B29-ijms-16-05072]\] and to the readers of the journal for any inconvenience.

The authors wish to replace the introduction of \[[@B28-ijms-16-05072]\] with the following:

1. Introduction
===============

Aromatase is a cytochrome P-450 dependent enzyme, which catalyzes the biosynthesis of estrogens from androgens. Aromatase inhibitors (AIs) control the level of estrogens and have been effectively used in the treatments of estrogen-dependent breast cancer \[[@B1-ijms-16-05072],[@B2-ijms-16-05072],[@B3-ijms-16-05072]\]. AIs are classified into two types: steroidal aromatase inhibitors (SAIs) and non-steroidal aromatase inhibitors (NSAIs) \[[@B4-ijms-16-05072]\]. NSAIs bind to the enzyme active site by competing with the substrate, and they are mostly azole type compounds such as anastrozole and letrozole \[[@B5-ijms-16-05072]\]. However, SAIs are converted by the enzyme to reactive intermediates and bind irreversibly to the enzyme active site by simulating the natural substrate androstenedione, which cause to inactivation of aromatase \[[@B6-ijms-16-05072]\]. Among SAIs, formestane was used by intramuscular injection during the early 1990s, which is not used nowadays. Instead of formestane, exemestane is widely used because of its oral activation \[[@B7-ijms-16-05072]\]. Though anastrazole, letrozole, and exemestane are used clinically, they still have some major side effects, such as heart problems, musculoskeletal effects, and bone toxicity \[[@B8-ijms-16-05072]\]. For this reason, it is necessary to develop other potent and specific molecules with lower side effects.

Quantitative structure-activity relationship (QSAR) methods have been widely applied to assist the design of new drug candidates nowadays \[[@B9-ijms-16-05072],[@B10-ijms-16-05072],[@B11-ijms-16-05072],[@B12-ijms-16-05072],[@B13-ijms-16-05072],[@B14-ijms-16-05072],[@B15-ijms-16-05072],[@B16-ijms-16-05072]\]. Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) are two of the most widely used three-dimensional quantitative structure-activity relationship (3D QSAR) methodologies. At various intersections of a regular three-dimensional lattice, CoMFA uses Lennard-Jones and Coulomb potential fields to calculate the energies of steric and electrostatic interactions between the compound and the probe atom, respectively. The results calculated by these two potential functions can be represented as a three-dimensional "coefficient contour" map \[[@B17-ijms-16-05072]\]. However, in order to avoid some inherent deficiencies caused by the Lennard-Jones and Coulomb potential functions, CoMSIA calculates the energies of interactions between the molecular atoms and the probe atom by introducing Gaussian function for the distance dependence. The contour maps obtained by the CoMSIA approach can show how steric fields, electrostatic fields, hydrophobic fields, hydrogen bond donor (HBD), and hydrogen bond acceptor (HBA) influence the activity of inhibitors \[[@B18-ijms-16-05072]\].

Pharmacophore modeling can provide valuable insight of interactions between ligands and receptors. A pharmacophore model shows the ensemble of steric and electrostatic characteristics of different compounds. Therefore, when one class of inhibitors is found, new classes of inhibitors can be discovered by a pharmacophore model, and pharmacophore searching is a good way to find various chemical structures with the same features, which is a method of choice for the first round of compound selection \[[@B19-ijms-16-05072],[@B20-ijms-16-05072],[@B21-ijms-16-05072]\].

A series of SAIs, shown in Table 1, have been reported in the recent literatures \[[@B22-ijms-16-05072],[@B23-ijms-16-05072],[@B24-ijms-16-05072],[@B25-ijms-16-05072],[@B26-ijms-16-05072],[@B27-ijms-16-05072]\]. To understand the structural requirements for inhibitory activity and design more potent agents, 3D QSAR studies were performed for the fist time for these SAIs using CoMFA and CoMSIA. In addition, 3D pharmacophore models were created and the selected best model was used as a 3D query for virtual screening against NCI2000 database. The biological activities of hit compounds were further predicted by using CoMFA and CoMSIA models.
